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Objective: To improve physicians’ ability to discriminate tuberculous from malignant pleural
effusions through a simple clinical algorithm that avoids pleural biopsy.
Design: We retrospectively compared the clinical and pleural fluid features of 238 adults with
pleural effusion who satisfied diagnostic criteria for tuberculosis (nZ 64) or malignancy
(nZ 174) at one academic center (derivation cohort). Then, we built a decision tree model
to predict tuberculosis using the C4.5 algorithm. The model was validated with an independent
sample set from another center that included 74 tuberculous and 293 malignant effusions
(validation cohort).
Results: Among 12 potential predictor variables, the classification tree analysis selected four
discriminant parameters (age > 35 years, pleural fluid adenosine deaminase > 38 U/L,
temperature 37.8 C, and pleural fluid LDH> 320 U/L) from the derivation cohort. The
generated flowchart had 92.2% sensitivity, 98.3% specificity, and an area under the ROC curve
of 0.976 for diagnosing tuberculosis. The corresponding operating characteristics for the vali-
dation cohort were 85.1%, 96.9% and 0.958.
Conclusions: Applying a decision tree analysis that contains simple clinical and laboratory data
can help in the differential diagnosis of tuberculous and malignant pleural effusions.
ª 2008 Elsevier Ltd. All rights reserved.973248100x2431; fax: þ34
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Tuberculosis and cancer represent the two most frequent
causes of exudative pleural effusions with predominantly
mononuclear cells in pleural fluid.1,2 Unfortunately,.
1160 J.M. Porcel et al.isolation of Mycobacterium tuberculosis in pleural fluid is
difficult (as well as a late event) because tuberculous pleu-
risy is primarily an immunological process with a small num-
ber of tuberculous bacilli.3 The demonstration of
granuloma in a biopsy specimen from the parietal pleura
suggests tuberculous pleuritis. However, this procedure
has been questioned because of the availability of pleural
fluid surrogate markers, such as adenosine deaminase
(ADA) and interferon-gamma, which are accurate enough
in supporting a diagnosis of tuberculous pleuritis.4,5 On
the other hand, a major obstacle in diagnosing malignant
effusions is the presence of false negative cytological re-
sults in about 40% of cases.6 Needle biopsy of the pleura
has a low sensitivity in detecting malignancy and thoraco-
scopy, which can be a definitive procedure for both tuber-
culosis and neoplasm, is invasive and not widely available.
Decision analysis techniques are a systematic approach
to decision making in complex situations under conditions
of uncertainty. A decision tree is a flowchart for modeling
a decision analysis. It consists of a starting point (i.e., the
clinical question to be addressed in the analysis) as well as
branching points (i.e., points at which alternatives become
possible).7 To our knowledge, no study has previously ad-
dressed the common clinical dilemma of differentiating tu-
berculosis from malignant pleural effusions through
a decision tree analysis.
The present study uses classification tree analysis to
develop a clinical algorithm for discriminating tuberculous
from malignant pleural effusions. We hypothesized that
a simple flowchart incorporating basic clinical and pleural
fluid data can predict with high sensitivity and specificity
the probability of tuberculosis, thus preventing in most
cases the performance of invasive diagnostic procedures.
Materials and methods
Patients and measurements
The local ethics committee of the two participating centers
approved this study and all subjects signed written in-
formed consent. We retrospectively compared clinical
(gender, age, temperature), radiological (effusion size
and laterality), and pleural fluid (total leukocyte count,
differential white cell count, glucose, protein, lactate
dehydrogenase (LDH), ADA and pH) data from patients
with tuberculous and malignant effusions. Using these 12
variables, we then conducted classification tree analysis to
mathematically derive an algorithm that accurately dis-
criminated between the two conditions.
The sample used to develop the decision tree (derivation
cohort) included all patients with demonstrated tubercu-
lous and malignant effusions identified at the Vall d’Hebron
University Hospital in Barcelona (Spain) from 1995 to 2006.
Data collected from tuberculous and malignant effusion
cases at the Arnau de Vilanova University Hospital in Lleida
(Spain) during the same period of time were used to
validate the decision tree (validation cohort).
A pleural effusion was categorized as malignant if
malignant cells were demonstrated in pleural fluid or
pleural biopsy. Tuberculous pleuritis was diagnosed if
ZiehleNeelsen stains or Lowenstein cultures of pleuralfluid, sputum, or pleural biopsy tissue samples were
positive or a pleural biopsy specimen showed granulomas
in the parietal pleura. Fever was defined as a temper-
ature 37.8 C, and pleural effusions were deemed to be
large if they occupied two-thirds or more of the
hemithorax.
Biochemical measurements on pleural fluid samples
were carried out on discrete analyzers (Hitachi models
717, 917 or Modular DP, Roche Diagnostics, Mannheim,
Germany) using standardized photometric methods. Spe-
cifically, pleural ADA activity and pH were assessed with an
automated ultraviolet kinetic test (Roche Diagnostics,
Barcelona, Spain) and a blood gas machine, respectively.
White blood cells were manually counted in a Thoma
chamber.
Statistical analysis
Continuous data are presented as medians (quartiles)
according to their non-parametric distribution. We used
Fisher’s exact test or ManneWhitney U test for group com-
parisons of categorical and continuous variables,
respectively.
Discrimination of tuberculous and malignant effusions
was accomplished using the C4.5 method for decision tree
analysis implemented through Weka 3.4 statistical software
(The University of Waikato, New Zealand).8 Classification
trees discriminate between outcome classes (e.g., tubercu-
losis vs. malignancy) by first searching the range of each po-
tential predictor (e.g., a given pleural fluid parameter) and
finding the split that maximizes the likelihood of the given
data set. Within each resulting subset (or node), the algo-
rithm again searches the range of each variable to choose
the optimal split. This process is continued until all obser-
vations are perfectly discriminated, or the sample size
within a given node is too small to divide further (e.g.,
nZ 5 or less). The final output of the resulting classification
tree is a graphical display of decision criteria for each split
as well as the resulting predicted probabilities of being
a given case across the final splits (i.e., terminal nodes).
A 10-fold internal cross-validation analysis was performed
as an initial evaluation of the test error of the algorithm.
Briefly, this process involved splitting up the data set into
10 random segments and using nine of them for training
and the 10th as a test set for the algorithm. Of note, for us-
ing the C4.5 decision tree, data must be available for all
variables in the model.
Finally, we evaluated the performance of the decision
algorithm with respect to sensitivity, specificity, likelihood
ratios and area under the receiver operating characteristic
curve (AUC), both in the derivation and the validation
cohorts. P values< 0.05 were considered statistically signif-
icant. Calculations other than the decision tree were per-
formed with a statistical software package (SPSS version
11.5; Chicago, IL, USA).
Results
A total of 64 tuberculous effusions and 174 malignant
effusions formed the learning set (derivation cohort), which
generated the decision algorithm. The decision tree was
Table 1 Diagnostic criteria among the study populationa
Cause of the pleural
effusion
Derivation
cohort, no.
Validation
cohort, no.
Tuberculosis
Culture of pleural fluid
(Lowenstein)
40 41
ZiehleNeelsen staining
of sputum
18 23
Pleural granulomas 6 10
Total 64 74
Malignancy
Pleural fluid cytology 133 273
Pleural biopsy 41 20
Total 174 293
a Both cohorts included a number of patients meeting more
than one diagnostic criterion.
A decision tree for tuberculous pleurisy 1161then tested using collected data from 74 new tuberculous
effusions and 293 malignant effusions (validation cohort).
Previously, 19 and 25 cases from the derivation and
validation cohorts, respectively, were excluded from the
analysis, because data were not available on all variables
used in the C4.5 decision tree.
Table 1 summarizes the methods used for diagnosing
tuberculous and malignant effusions. The malignant pleural
effusions in the derivation cohort included lung (71),
unknown primary (21), breast (18), hematologic (16),
mesothelioma (14), gynecologic (11), gastrointestinal (8),
and other tumors (15). Likewise, primary sites of the
tumor in the validation cohort were as follows: lung (98),
breast (61), hematologic (31), unknown primary (30), gyne-
cologic (30), mesothelioma (12), gastrointestinal (8), and
others (23).
Characteristics of the tuberculous and malignant effu-
sions used to create and test the decision tree are shown inTable 2 Patients’ characteristics within the derivation cohort
Tuberculous effusions (nZ 64)
Clinical data
Age, years 33.5 (24e48)
Male gender 44/64 (68.8%)
Fever 49/64 (76.6%)
Large effusion 6/64 (9.4%)
Unilateral effusion 59/64 (92.2%)
Pleural fluid data
Leukocytes, 109/L 2.56 (1.50e4.28)
Lymphocytes, % 81 (61e93)
Glucose, mg/dL 79 (59e95)
Protein, g/L 52 (48.2e54)
LDH, U/L 971 (650e1896)
ADA, U/L 72.5 (58.3e98.8)
pH 7.34 (7.25e7.39)
LDH, lactate dehydrogenase; and ADA, adenosine deaminase.Tables 2 and 3, respectively. Except for the laterality of
pleural effusions, both cohorts were homogeneous.
Fig. 1 displays the decision tree produced by the C4.5
method to discriminate tuberculous from malignant effu-
sions. The classification tree identified the following pre-
dictors of tuberculous pleurisy in order of importance:
age< 35 years, pleural fluid ADA> 38 U/L, presence of
fever and pleural fluid LDH> 320 U/L. In the derivation
set group, the tree had a sensitivity of 92.2% (95% CI,
85.6e98.8%), a specificity of 98.3% (95%CI, 96.3e100%),
and an AUC of 0.976 (95% CI, 0.946e1) for identifying effu-
sions of tuberculous origin. Similarly, the decision tree per-
formed with 85.1% sensitivity (95% CI, 77e93.2%), 96.9%
specificity (95% CI, 95e98.9%), and AUC of 0.958 (95% CI,
0.929e0.987) in the validation cohort. In this latter group,
only 9 of 293 (3%) malignant effusions (six lymphomas, one
lung adenocarcinoma, one breast cancer, and one cancer of
unknown origin) would have been misclassified as
tuberculosis.
Discussion
Based on readily available clinical and pleural fluid data,
we developed a very simple and accurate decision model
for the differential diagnosis of tuberculous and malignant
effusion, a key dilemma when confronted with a lympho-
cytic pleural exudate. Although the gold standard for the
diagnosis of tuberculous pleurisy remains microbiological
(i.e., demonstration of tubercle bacilli in the pleural fluid,
sputum or pleural biopsy specimen) or histological (i.e.,
demonstration of pleural granulomas), the proper diagnos-
tic approach is still debated. Central to the controversy is
the role of needle biopsy of the pleura vs. the use of pleural
fluid ADA or, less commonly, interferon-gamma measure-
ments alone.9
Avoidance of closed pleural biopsy is clinically attractive.
In this regard, few studies have evaluated the utility of
clinical and laboratory data in diagnosing tuberculous
pleural effusion on the basis of mathematical predictive
models.10e13 In an early study from Spain, 47 variablesMalignant effusions (nZ 174) P value
68.5 (59e75) <0.001
95/174 (54.6%) 0.055
19/174 (10.9%) <0.001
58/174 (33.3%) <0.001
165/174 (94.8%) 0.534
1.70 (0.90e3.30) 0.003
80 (65e90) 0.461
102 (83e128) <0.001
46 (40e51) <0.001
525 (365e852) <0.001
17 (12e24) <0.001
7.39 (7.32e7.42) 0.004
Table 3 Patients’ characteristics within the validation cohort
Tuberculous effusions (nZ 74) Malignant effusions (nZ 293) P value
Clinical data
Age, years 33 (25e44.3) 70 (60.5e77) <0.001
Male gender 55/74 (74.3%) 146/293 (49.8%) <0.001
Fever 55/74 (74.3%) 21/293 (7.2%) <0.001
Large effusion 3/71 (4.2%) 50/250 (17.1%) 0.006
Unilateral effusion 68/71 (95.8%) 231/274 (84.3%) 0.010
Pleural fluid data
Leukocytes, 109/L 1.59 (0.54e3.27) 0.88 (0.40e1.71) <0.001
Lymphocytes, % 88 (71e95) 84 (61e94) 0.166
Glucose, mg/dL 77 (55e95) 108 (86e133) <0.001
Protein, g/L 53.1 (47.6e57.3) 43.7 (38.2e49) <0.001
LDH, U/L 911 (675e1703) 545 (340e1016) <0.001
ADA, U/L 63.9 (50.4e91.2) 16.0 (10.2e23.4) <0.001
pH 7.36 (7.30e7.43) 7.41 (7.34e7.47) 0.002
LDH, lactate dehydrogenase; and ADA, adenosine deaminase.
1162 J.M. Porcel et al.obtained from the medical records of 78 patients with
tuberculous and 111 with non-tuberculous effusions were
entered in a stepwise discriminant analysis.10 The most
powerful predictor of tuberculous effusion was a discrimi-
nant function (formula) that included the patient’s age
(years), tuberculin skin test (mm of induration at 48 h),
leukocyte count in peripheral blood (cells/mm3), and blood-
stained pleural fluid (presence or absence). This discrimi-
nant function showed a sensitivity of 90%, specificity of
87% and accuracy of 88%. ADA was not included among the
tested variables and the results need further validation. In
a second report from Brazil, another equation created
with five variables (pleural fluid ADA> 39 U/L, pleural fluid
protein> 4.1 mg/dL, >81% of lymphocytes in pleural fluid,
duration of disease< 45 days, and peripheral white cellTuberculosis
35TB/0M
Malignancy
1TB/166M
Tuberculosis
4TB/1M
Malignancy
4TB/5M
PF LDH > 320 U/L Tuberculosis
20TB/2M
Fever?
PF ADA > 38 U/L
Age > 35 years?
Tuberculous or malignant pleural effusion?
64TB/174M
YesNo
No Yes
No
Yes
Yes
No
Figure 1 A decision tree for tuberculous and malignant effu-
sion discrimination. Inside the boxes is the number of tubercu-
lous (TB) and malignant (M) effusions from the derivation
group. PF, pleural fluid; ADA, adenosine deaminase; and LDH,
lactate dehydrogenase.count< 6000 cell/mm3) performed the best, in a logistic
regression model, to discriminate 104 tuberculous from
111 non-tuberculous effusions (AUC 0.991).11 External vali-
dation of the results from this study was lacking. In addition,
a prediction rule using a complicated fractional polynomial
equation to distinguish tuberculosis from malignancy, as in
the above-mentioned studies, would require automation
to be applied in the clinical setting. A third study devised
a multivariate scoring system to discriminate pleural effu-
sions caused by tuberculosis from those caused by malig-
nancy.12 Four parameters were selected and scored by the
model as predictive of tuberculosis, namely pleural fluid
ADA 40 U/L (five points), age 35 years (two points), tem-
perature 37.8 C (two points), and pleural red blood cell
count 5 109/L (two points). Summated scores of 5
yielded excellent discriminating characteristics (sensitivity
95%, specificity 94%, AUC 0.987). The study was flawed by
the inclusion of a significant number of probable rather
than certain cases in both the tuberculous and malignant
groups. This study, also, was not validated. Lastly, a recent
prospective study compared seven biological markers in the
pleural fluid of 45 patients with malignant, 15 with para-
pneumonic and 12 with tuberculous pleural effusions. The
application of a multinomial logit model revealed ADA and
C-reactive protein as the most important parameters for
discriminating between groups.13 Specifically, the combina-
tion of pleural fluid ADA> 42.4 U/L and C-reactive pro-
tein < 5.5 mg/dL resulted in the correct classification of
91.7% of tuberculous effusions. Limitations of this study
were the small sample size and the absence of lymphoma-
tous effusions among the malignant group.
The present investigation supports some previous find-
ings, particularly the diagnostic utility of the ADA measure-
ment as a marker of tuberculous pleurisy. The inclusion of
other parameters in the classification tree, such as age or
fever, is logical. It is accepted that tuberculosis tends to
occur in younger patients and that most of them are febrile
as compared with patients with a malignancy.9 Paradoxi-
cally, a high pleural LDH level was selected in the last
tree node as indicative of malignant effusion, despite the
greater mean concentrations of this enzyme in tuberculosis
A decision tree for tuberculous pleurisy 1163than in malignancy. Probably, the weight of this variable is
negligible because 94% of effusions in both cohorts had al-
ready been classified before arriving at this point in the
tree. Our classification tree performed as well as logistic re-
gression models10,11 in identifying tuberculosis, but is much
easier to interpret for clinical use. Unlike previous studies,
the current proposed four-variable algorithm model was
validated using an independent sample of patients, thereby
demonstrating a very reliable discriminating ability (sensi-
tivity 85.1%, specificity 96.9%, AUC 0.958), leading to the
correct classification (accuracy) of 94.6% of patients. These
figures are comparative to those obtained from the combi-
nation of histology and culture in pleural biopsy specimens
for diagnosing tuberculous pleurisy.14 Notably, lymphoma
was the most frequently misclassified (6/31, 19%) tumor
type after fitting the decision tree. This was not an unex-
pected finding, since hematologic malignancies have higher
mean pleural fluid ADA levels than any other neoplasm
invading the pleural surfaces.15
This study has some limitations. First, the decision tree
is valid only for the differential diagnosis of tuberculous
and malignant effusions. However, other non-tuberculous
pleural effusions, such as those secondary to heart failure
or pneumonia, are easily diagnosed on clinical grounds.
Second, our study was retrospective, but the potential
impact of this limitation is minimal because the decision
tree includes only objective clinical characteristics and
laboratory parameters. Furthermore, we used strict criteria
to define the outcome variable (tuberculosis vs. malig-
nancy) to minimize misclassification bias. Finally, the
prevalence of both tuberculous and malignant effusions
will affect the performance of the rule. The latest available
data (2005) shows that the prevalence of tuberculosis in
Spain is 22/100,000 inhabitants/year, while in the United
States it is 3.4/100,000 inhabitants/year, far from the
>500/100,000 inhabitants/year in areas of southern
Africa.16 In Spain, tuberculosis accounts for 10e15% of all
pleural effusions submitted to thoracentesis.1,2 Although
an evaluation of the tree performance in areas with low-
pretest probability of tuberculosis is desirable, such a study
is difficult to accomplish. However, even in those cases,
ADA will still retain its high negative predictive value.
The general disadvantage for diagnosing pleural tuber-
culosis on the basis of pleural fluid biochemistries (i.e.,
ADA) is the failure to provide antituberculous susceptibility
data, given concerns for drug-resistant forms of the
disease. In Catalunya, the geographical region of Spain
where the two participant centers are located, only 24 of
735 (3.2%) M. tuberculosis isolates exhibited any first-line
drug resistance in tests performed in 2004.17 In the United
States, a recent epidemiological survey found that 9.9% of
patients with pleural tuberculosis had isolates that were
resistant to at least one first-line drug, although multi-
drug resistance (resistance to both isoniazid and rifampin)
was only 1%.18 In areas with low drug-resistance rates,
the diagnosis of tuberculous pleurisy based solely upon
pleural fluid ADA measurement seems reasonable.14
In conclusion, the generated decision tree retains in-
tuitive appeal and can easily be applied by the clinician.
Our findings can be briefly summarized: a young patient
with fever and a lymphocytic pleural exudate with high ADA
activity and negative cytological studies has a tuberculouspleurisy, until proven otherwise. Accordingly, we advocate
the initiation of an antituberculous therapy in this partic-
ular setting. Like all prediction rules, this one should be
used with appropriate clinical judgment. In addition to
pleural fluid cultures, sputum induction should also be
obtained, when possible. Yet, invasive diagnostic proce-
dures, such as pleural biopsy, could be reserved for cases
unresponsive to treatment. The proposed clinical rule may
be adequate for areas with a prevalence of tuberculosis
comparable or greater to that reported in Spain, but less
tenable if a lower disease prevalence or higher drug-
resistant rates exist.Conflict of interest
The authors have no conflict of interest.
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